CMS Quit Test Of Pricey Cancer Treatment Amid Concerns Over Industry Role

July 12, 2018

Medicare and Medicaid administrators earlier this year quietly killed a plan to pay for a breakthrough, half-million-dollar cancer treatment based on how well it worked, scuttling one of the Trump’s administration’s first and most highly touted attempts to lower the cost of drugs. The payment deal for Swiss drug giant Novartis’ Kymriah therapy was suspended […]

Drugmakers Cancel Price Hikes After California Law Takes Effect

July 12, 2018

A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of […]

Trump Admin Rejects Massachusetts Drug Pricing Proposal

June 28, 2018

The Trump administration on Wednesday rejected a request from Massachusetts that state officials argued would have given them more flexibility over its Medicaid program and greater negotiating power over drug companies.   The state’s Health and Human Services department asked the administration to approve a plan that would have allowed the state to limit what […]

Senate Panel Schedules Vote On Controversial Drug Pricing Bill

June 7, 2018

The Senate Judiciary Committee announced Tuesday that it is moving ahead this week on a controversial bill aimed at lowering drug prices.   The bill, known as the Creates Act, seeks to crack down on drug companies using tactics to delay the introduction of cheaper generic drugs onto the market. It has been stalled for […]

Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price

May 3, 2018

Regeneron Pharmaceuticals and partner Sanofi have cut an unusual deal with Express Scripts, the nation’s largest drug-buying middleman. The two drug makers will cut the price of their $14,000-a-year cholesterol-lowering therapy alirocumab (Praluent). In return, Express Scripts will quickly approve treatment requests. The deal also sidelines Amgen, whose rival heart drug evolocumab (Repatha) will no […]

Novartis matches Gilead on price in new CAR-T use

May 3, 2018

Novartis’ CAR-T therapy Kymriah will be available in the US to adults with relapsed large B-cell lymphoma – bringing the cell therapy into direct competition with Gilead’s rival at exactly the same price.   Kymriah (tisagenlecleucel) is also available in advanced paediatric B-cell precursor acute lymphoblastic leukaemia but in this first indication the Swiss pharma […]

Federal Appeals Court Puts Chill On Maryland Law To Fight Drug Price-Gouging

April 19, 2018

States continue to battle budget-busting prices of prescription drugs. But a federal court decision could limit the weapons available to them — underscoring the challenge states face as they, in the absence of federal action, go one-on-one against the powerful drug industry. The 2-to-1 ruling Friday by the U.S. 4th Circuit Court of Appeals invalidated […]

Certara Acquires Analytica Laser, a Leader in Market Access, Health Economics and Outcomes Research (HEOR), and Real-world Evidence Solutions

April 12, 2018

Acquisition adds real-world effectiveness prediction and value assessment to Certara’s model-informed drug development and regulatory science decision-making portfolio Certara®, the global leader in model-informed drug development and regulatory science, today announced that it has acquired Analytica Laser, a global research consultancy that uses health economics and outcomes research (HEOR) and real-world data to provide the […]

CVS’ Caremark Customers Now Have A Tool That Makes It Easier To Find Less Expensive Drugs

April 12, 2018

The drugstore chain is introducing a system that will check for less expensive alternatives, higher quantities at lower costs and discounts. CVS hopes it can help lower costs for its customers and in doing so, make sure they pick up their prescriptions. Drug costs are rising, and patients are paying more of their health-care bills […]

Why We May Lose Generic Drugs

April 12, 2018

The mood at the annual generic drug industry confab in Orlando in February was especially somber. The discussion during one panel was all about plunging drug prices, consolidation among drug-buying groups, and the increasingly cutthroat nature of the business. A top executive at Israel-based Teva Pharmaceutical Industries Ltd., the No. 1 supplier of generics in the […]

AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe

April 12, 2018

REDWOOD CITY, Calif., April 11, 2018 /PRNewswire/ — AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported the publication of a report commissioned by AcelRx analyzing the economic burden associated with administration of intravenous (IV) morphine for acute […]